Insider filing · BBIO
Frank McCormick
Director
profile →
BridgeBio Pharma, Inc.
BBIO · Healthcare · 71 filings in 24 months
ticker →
Frank McCormick sold $13.2M of BridgeBio Pharma (BBIO)
Executed Oct 29 2025, disclosed Oct 31 2025, 2 days later.
Value, as filed
$13.2M
198,359 sh across 5 lots
Executed
Oct 29 2025
the trade date, as filed
Disclosed
Oct 31 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
FMFrank McCormick (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in BridgeBio Pharma, Inc. (BBIO). The largest single filing was $13.2M of BBIO (198,359 sh across 5 lots, as filed), executed Oct 29 2025.
The name
BBIOHealthcare · BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Frank McCormick in BBIO
BBIOSALE
BridgeBio Pharma, Inc.
$107K1,641 sh × $65.00
Exec Oct 27 2025
Filed Oct 29 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $3.9M
74,000 sh × $53.16
Exec Sep 5 2025
Filed Sep 8 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. $4.4M
100,000 sh × $44.23
Exec Jun 24 2025
Filed Jun 26 2025 · 5:30 PM ET